Status: Not yet recruiting
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 6, 2026Locations: 1
Eligibility criteria
Participants must have histologically or cytologically confirmed squamous cell c... [+25]
Has a history of documented severe dry eye syndrome, severe Meibomian gland dise... [+21]